RAM
VRTX icon

Readystate Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Readystate Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357K Buy
+800
New +$373K 0.02% 677
2025
Q2 		– Sell
-5,500
Closed -$2.67M – 946
2025
Q1 		$2.67M Sell
5,500
-13,800
-72% -$6.43M 0.09% 283
2024
Q4 		$7.77M Buy
19,300
+1,500
+8% +$695K 0.24% 96
2024
Q3 		$8.28M Buy
17,800
+16,200
+1,013% +$7.78M 0.15% 258
2024
Q2 		$750K Sell
1,600
-27,400
-94% -$11.9M 0.02% 391
2024
Q1 		$12.1M Buy
29,000
+19,500
+205% +$8.24M 0.17% 123
2023
Q4 		$3.87M Buy
9,500
+8,900
+1,483% +$3.29M 0.13% 155
2023
Q3 		$209K Hold
600
– – 0.01% 486
2023
Q2 		$211K Buy
+600
New +$202K 0.02% 270

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Readystate Asset Management's VRTX Position: Q1 2025 in Review

Readystate Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 11,058 shares — an estimated $5.15M sold.

Readystate Asset Management first reported a position in VRTX in Q4 2023 and held it in 4 quarters. The position peaked at $4.45M in Q4 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Readystate Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Readystate Asset Management sold 11,058 Vertex Pharmaceuticals shares in Q1 2025, an estimated $5.15M.
  • Readystate Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Readystate Asset Management's Vertex Pharmaceuticals position peaked at $4.45M in Q4 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.